"I have to thank you for the story about Nuvilex that you wrote Feb 21 putting the stock on my radar...since then the stock has gone from 5 cents to 17 cents! I researched the company a bit and only invested what I could afford to lose since it's a penny stock, but the returns are nice. Nuvilex seems to have some big upside. This is one of the reasons I read your blog each day...you cover many different areas of interest beyond domains. Keep up the great work on your blog...it's always a great read!"
And some that acted on our advice already have. And for many it's not the first time. our records with Alcatel and Apple are well documented.
What's different about this one (in addition to getting in on it at its very humble beginnings is Nuvilex (OTCQB: NVLX) has unlimited upside potential because its proprietary living cell encapsulation technology is a true platform that has could serve a benefit to countless indications. The experts at Nuvilex (OTCQB: NVLX) also intend to utilize cannabinoids (active ingredients in marijuana) in developing treatments for an array of diseases and conditions, through its subsidiary Medical Marijuana Sciences, Inc. So, the company appears to be in an ideal situation to develop combination treatments that use both technologies for deadly diseases, such as pancreatic cancer.
Now you can fall for the hype and get duped on scams like Facebook and Groupon. Or you could get educated and start investing in sure bets like Apple and Alcatel, innovations that actually solve pressing problems in people's lives and make for the empowerment and improvement of all mankind.
Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, posits that given its current stage of clinical development it is possible that Nuvilex Inc. (OTCQB: NVLX) may eventually attract the interest of large pharmaceutical firms seeking to gain access to its highly efficacious and proprietary technology platform. Nuvilex Inc. (OTCQB: NVLX) is an international firm with a live-cell encapsulation technology initially directed to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.
Any arrangement typically begins with a lengthy due diligence process with no guarantees that anything material arises from such due diligence. Still, it is not uncommon that the process results in some form of partnership or collaboration. These collaborations often contain an agreement to assist in funding future research and development, a royalty arrangement should development lead to regulatory approval, and occasionally lead to a direct investment in the targeted company itself.
While many companies enter Phase III clinical trials without a partner, this prospective event is relevant to companies like Nuvilex Inc. (OTCQB: NVLX) since it is not uncommon for collaborative relationships to be formalized ahead of a Phase III clinical trial.
Additional detail regarding the structure of biotechnology collaboration relationships as well as other articles and Nuvilex reports can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
Said Corey Graham on his blog:
Nuvilex (NVLX) Developing a Type of “Artificial Pancreas” to Cut Into $245 Billion Cost of Diabetes
The American Diabetes Association said this month that the price tag for diabetes cost the United States an estimated $245 BILLION in 2012. That’s a 40 percent growth from six years ago, simply due to an increasing number of people are being diagnosed at a frightening rate. At the end of 2012, 22.3 million people, or 7% of the United States population, will have diabetes. The International Diabetes Federation estimated that 366 MILLION individuals were diagnosed with diabetes in 2011 (about 180 million more were estimated to be undiagnosed) and that number is expected to climb to 552 MILLION by 2030, if “urgent action” is not taken right away. That’s 1 in every 10 people on the earth! Unbelievably, the number is predicted to grow to 1 in every 3 people on the planet by 2050 at its current rate of growth. Is there any wonder why the government, who carries the check for about 62% of the costs, met on Capitol Hill to determine how to curtail the spiraling costs?
“We have an astonishing epidemic of diabetes that is driving health care expenses excessively. ... Unless we do something to stop diabetes, the economic toll will continue to grow,” said the American Diabetes Association’s Chief Scientific and Medical Officer, Robert E. Ratner, MD, at a recent meeting on Capitol Hill.
Now, you don’t have to be a mathematician, economist, politician, or be someone who has received a higher learning of any variation to realize what a drain diabetes is on the country and that something desperately needs to be done, especially with all of the budget bickering going on in Washington at this moment. Remember those cost amounts are just for the U.S. Can you imagine the true cost globally? There’s a good reason that Congress has tasked the FDA to accelerate new medications to the market that meet areas of great unmet medical need, like diabetes, the single most expensive long-term disease known to man. Investors take notice; find a company that has a promising solution NOW!
The cost of diabetes in the U.S. has increased 40% in 5 years to a massive $245 BILLION in 2012! 7% of the U.S. population has diabetes today. At the current rate, 33% of the world’s population will have diabetes in 2050!
There are $80 per share companies like Johnson & Johnson (NYSE: JNJ) that have a promising diabetes medicine that is expected to garner FDA approval in March, but the approval is already baked-into the price per share and at $80, the potential is definitely controlled. Undervalued and undiscovered plays like Nuvilex, Inc. (OTCBB: NVLX) are the companies that have unprecedented potential. At 4.3 cents, the biotech – who is prepping for late-stage clinical trials with their pancreatic cancer treatment – commands an extremely low market capitalization and an equally attractive price point for the educated investor.
Nuvilex’s cell encapsulation technology is the type of dire need technology that could have a considerable impact on the diabetes industry. Pioneering work in a well documented study called the “Edmonton Protocol” showed that pancreatic islet cell (insulin-producing cells) transplantations could hold the answer to a life-changing diabetes therapy by eradicating the need for daily administration of insulin either by injection or by using an insulin “pump.” However, the issue was that the cells used were allogeneic (derived from a donor different from the recipient) and powerful immunosuppressive medications were required almost for the duration of the patients’ lives to stop the recipient’s immune system from targeting and terminating the implanted islet cells. It doesn’t take a specialist to realize that enduringly repressing a patient’s immune system is obviously not a good idea. Nuvilex’s cell encapsulation technology possibly has the solution, as supported by preclinical research in animals that could potentially bring pancreatic islet cell transplants to the hundreds of millions of people in need.
Nuvilex did what many might think to be impossible. Read closely. They took pancreatic inset cells from pigs and encapsulated them with their unique technology. In other words, they put the cells inside of tiny, cellulose-based, capsules that have pores in them so that nutrients for the cells can enter and waste products from the cells as well as “beneficial” factors from the cells can exit; in this case, the “beneficial” ingredient was insulin. They then implanted the encapsulated islet cells into diabetes suffering rats. Within a few days, the sugar level of the rats stabilized and stayed that way for the 180 days of the study! When the capsules were removed from the rats, the cells inside were still alive and operative – an amazing finding in its own right.
The company also appears to have bypassed the allogeneic problem! Although islet cells from one species (pigs) were implanted into a totally different animal (rats), the islet cells inside the capsules were protected from the recipients’ immune systems because the pores in the capsules are too small to permit immune system cells to enter the capsules and extinguish the islet cells inside them and too tiny to permit the encapsulated islet cells to escape and then be demolished.
In essence, Nuvilex has figured out a way to invent a type of “artificial” pancreas to control sugar levels, effectively eradicating the need for daily, or recurrent, insulin administration. Amazing. The company has plans to repeat animal testing on a larger scale and then, if their original observations are repeated, will pursue conducting clinical trials to see if it will prove out in humans as well.
Preclinical animal studies demonstrated that Nuvilex was able to take insulin-producing cells from one animal and implant them into a different animal and essentially create a type of “artificial pancreas” to combat diabetes!
This is literally an “are you kidding me?”-type of a moment that Nuvilex was able to complete this preliminary study with such hopeful results. Many investors desire the company because of the captivating Phase 2 clinical research done with its cell encapsulation technology on advanced pancreatic cancer which demonstrated the potential of the technology because the clinical trial results outshined the historic results of the only FDA-approved single medication treatment for advanced, inoperable, pancreatic cancer. Others see great worth in the company’s Medical Marijuana Sciences subsidiary that will try to prove the benefits of ingredients of marijuana in the development of treatments for the deadliest strains of cancer. Few have had a hold on how Nuvilex’s unique cell encapsulation technology can be utilized in one of the biggest markets in the world, namely diabetes. Now you do.